Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM), March 2025 The Doxy-PEP Decision Making Tool supports prescribing doxycycline post-exposure prophylaxis (Doxy-PEP) to gay and bisexual men and transgender women at increased risk of syphilis. Suitable patients include those with recent syphilis or other STI diagnoses, periods of increased risk, or who wish to protect...
Updated guidelines for PEP (Post-Exposure Prophylaxis) after non-occupational and occupational exposure to HIV
Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM), June 2023 ASHM has updated the National Guidelines for Post-Exposure Prophylaxis (PEP) after non-occupational and occupational exposure to HIV . These guidelines outline the updated Australian recommendations for human immunodeficiency virus (HIV) post-exposure prophylaxis (PEP) following potential or known exposure...
New study on use of combined and progestogen-only hormonal contraception and breast cancer risk
Faculty of Sexual and Reproductive Healthcare, Royal College of the Obstetricians and Gynaecologists (UK), 22 March 2023 FSRH response to new study on use of combined and progestogen-only hormonal contraception and breast cancer risk: A new observational study by Fitzpatrick, et al., published in PLOS Medicine investigated the association between current or recent use of combined oral and...
Webinar: Supporting Primary Health Care Clinicians in SA in the Provision of Medical Abortion
SPHERE: NHMRC Centre of Research Excellence in Sexual and Reproductive Health for Women in Primary Care, October 2022 The primary objective of the webinar is to provide general practitioners, practice nurses and community pharmacists with the support required to initiate EMA services in their area. This will be undertaken by providing an overview of: • the context of South Australian legislation...
Update: Changes to HIV treatment access for people ineligible for Medicare
NAPWHA, ASHM, AFAO, May 2022 From 1st July, people with HIV who are ineligible for Medicare, and who previously received HIV medication through compassionate access schemes, will be required to transition to alternative access arrangements in order to receive government-funded treatment*. Option 1: individuals will need to engage in care with a public hospital-based physician and have their...
Changes in use of hormonal long‐acting reversible contraceptive methods in Australia 2006 – 2018
Changes in use of hormonal long‐acting reversible contraceptive methods in Australia between 2006 and 2018: A population‐based study Luke E. Grzeskowiak, Helen Calabretto, Natalie Amos, Danielle Mazza, Jenni Ilomaki ANZJOG First published: 23 October 2020, Abstract: Background Long‐acting reversible contraceptives (LARCs) are promoted internationally as a key strategy for reducing unintended...